
Instil Bio (TIL) Stock Forecast & Price Target
Instil Bio (TIL) Analyst Ratings
Bulls say
Instil Bio Inc. has witnessed a significant increase in its stock price, attributed to the positive unveiling of the full HARMONi-2 dataset, reflecting a nearly 500% valuation boost and suggesting potential future momentum with upcoming data from Summit Therapeutics. The company's DCF analysis estimates a firm value of approximately $884 million, underpinned by its innovative cell therapy pipeline which includes ITIL-306, a promising candidate targeting multiple solid tumors. Furthermore, Instil Bio's strategic positioning within the competitive landscape, particularly its pioneering efforts in combining checkpoint inhibition with anti-angiogenesis approaches, reinforces the potential for substantial growth and value generation.
Bears say
Instil Bio reported a net loss of $1.82 for the fourth quarter of 2024 and anticipates a significant increase in its 2025 net loss, projecting it to reach $11.51 per share, compared to a prior estimate of $3.65 per share. The company faces multiple risks that could hinder its prospects, including potential delays in clinical assessments of its candidates and a failure to produce favorable clinical data, especially concerning the AXN-2510 drug in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Additionally, there is a concern regarding medium- to long-term dilution risk, which could negatively impact shareholder value.
This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.
Instil Bio (TIL) Analyst Forecast & Price Prediction
Start investing in Instil Bio (TIL)
Order type
Buy in
Order amount
Est. shares
0 shares